Charles Brandes recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Charles Brandes (Trades, Portfolio) is the founder and former chairman of Brandes Investment Partners. He started the firm in 1974. Before retiring in 2018, he managed multiple portfolios, including the U.S. Equity and Global Equity Funds. He is the author of the book, “Value Investing Today.”
As a leading investment advisory firm specializing in managing a variety of global equity and fixed-income assets for investors worldwide, Brandes was among the first investment firms to invest globally using a value approach.
As of the latest 13F report, the guru’s equity portfolio contained 138 stocks valued at a total of $3.57Bil. The top holdings were ERJ(4.82%), CX(3.53%), and WFC(3.28%).
According to GuruFocus data, these were Charles Brandes (Trades, Portfolio)’s top five trades of the quarter.
Cigna Corp
Charles Brandes (Trades, Portfolio) reduced their investment in NYSE:CI by 158,105 shares. The trade had a 1.15% impact on the equity portfolio. During the quarter, the stock traded for an average price of $316.43.
On 02/13/2023, Cigna Corp traded for a price of $297.04 per share and a market cap of $88.24Bil. The stock has returned 32.67% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Cigna Corp has a price-earnings ratio of 13.89, a price-book ratio of 2.01, a price-earnings-to-growth (PEG) ratio of 0.64, a EV-to-Ebitda ratio of 11.11 and a price-sales ratio of 0.51.
The price-to-GF Value ratio is 1.10, earning the stock a GF Value rank of 3.
General Dynamics Corp
Charles Brandes (Trades, Portfolio) reduced their investment in NYSE:GD by 182,110 shares. The trade had a 1.01% impact on the equity portfolio. During the quarter, the stock traded for an average price of $243.94.
On 02/13/2023, General Dynamics Corp traded for a price of $232.19 per share and a market cap of $63.72Bil. The stock has returned 11.08% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, General Dynamics Corp has a price-earnings ratio of 19.03, a price-book ratio of 3.43, a price-earnings-to-growth (PEG) ratio of 5.29, a EV-to-Ebitda ratio of 13.99 and a price-sales ratio of 1.66.
The price-to-GF Value ratio is 1.12, earning the stock a GF Value rank of 3.
Embraer SA
Charles Brandes (Trades, Portfolio) reduced their investment in NYSE:ERJ by 3,316,103 shares. The trade had a 0.75% impact on the equity portfolio. During the quarter, the stock traded for an average price of $10.15.
On 02/13/2023, Embraer SA traded for a price of $12.355 per share and a market cap of $2.25Bil. The stock has returned -14.52% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Embraer SA has a price-earnings ratio of 156.39, a price-book ratio of 0.92, a EV-to-Ebitda ratio of 11.80 and a price-sales ratio of 0.58.
The price-to-GF Value ratio is 1.04, earning the stock a GF Value rank of 5.
Merck & Co Inc
Charles Brandes (Trades, Portfolio) reduced their investment in NYSE:MRK by 317,550 shares. The trade had a 0.72% impact on the equity portfolio. During the quarter, the stock traded for an average price of $102.22.
On 02/13/2023, Merck & Co Inc traded for a price of $108.7146 per share and a market cap of $275.63Bil. The stock has returned 45.59% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Merck & Co Inc has a price-earnings ratio of 19.04, a price-book ratio of 6.19, a price-earnings-to-growth (PEG) ratio of 2.51, a EV-to-Ebitda ratio of 14.59 and a price-sales ratio of 4.68.
The price-to-GF Value ratio is 1.02, earning the stock a GF Value rank of 5.
UBS Group AG
Charles Brandes (Trades, Portfolio) reduced their investment in NYSE:UBS by 1,790,708 shares. The trade had a 0.6899999999999999% impact on the equity portfolio. During the quarter, the stock traded for an average price of $17.01.
On 02/13/2023, UBS Group AG traded for a price of $21.805 per share and a market cap of $67.89Bil. The stock has returned 7.80% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, UBS Group AG has a price-earnings ratio of 9.73, a price-book ratio of 1.18, a price-earnings-to-growth (PEG) ratio of 2.32 and a price-sales ratio of 2.10.
The price-to-GF Value ratio is 1.21, earning the stock a GF Value rank of 3.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
